A recently published European real-world registry including 23,000 patients propensity-score matched with DM showed that liraglutide is superior to any dipeptidyl peptidase-4 (DPP-4) inhibitor in reducing MACE [19]. The gene discussed is DPP4; the disease is diabetes mellitus.